Healthcare -
Biotechnology - NASDAQ - US
$ 9.14
-8.23 %
$ 455 M
Market Cap
-2.5
P/E
1. INTRINSIC VALUE
Balance Sheet
Mineralys Therapeutics, Inc.
| Current Assets | 205 M |
| Cash & Short-Term Investments | 198 M |
| Receivables | 0 |
| Other Current Assets | 7.16 M |
| Non-Current Assets | 552 K |
| Long-Term Investments | 0 |
| PP&E | 53 K |
| Other Non-Current Assets | 499 K |
| Current Liabilities | 14.6 M |
| Accounts Payable | 479 K |
| Short-Term Debt | 0 |
| Other Current Liabilities | 14.2 M |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Mineralys Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 192 M |
| Operating Income | -192 M |
| Other Expenses | -14.6 M |
| Net Income | -178 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Mineralys Therapeutics, Inc.
| Net Income | -178 M |
| Depreciation & Amortization | 43 K |
| Capital Expenditures | -96 K |
| Stock-Based Compensation | 11.3 M |
| Change in Working Capital | 9.52 M |
| Others | -307 K |
| Free Cash Flow | -166 M |
Wall Street Analysts Price Targets
Mineralys Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for MLYS of $30 , with forecasts ranging from
a
low of
$30 to a high of $30 .
MLYS Lowest Price Target
Wall Street Target
30 USD
228.23%
MLYS Average Price Target
Wall Street Target
30 USD
228.23%
MLYS Highest Price Target
Wall Street Target
30 USD
228.23%
4. DIVIDEND
ANALYSIS
MLYS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Mineralys Therapeutics, Inc.
Sold
0-3 MONTHS
264 K USD 2
3-6 MONTHS
811 K USD 3
6-9 MONTHS
10.3 M USD 4
9-12 MONTHS
1.5 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 month ago
Jan 13, 2025
|
Sell 96.9 K
USD
|
Levy Adam Scott
CFO and Secretary
|
- 10657
|
9.0927 USD |
|
1 month ago
Jan 13, 2025
|
Sell 963
USD
|
Levy Adam Scott
CFO and Secretary
|
- 100
|
9.63 USD |
|
1 month ago
Jan 13, 2025
|
Sell 166 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 18333
|
9.0592 USD |
|
3 months ago
Nov 11, 2024
|
Sell 75.4 K
USD
|
Rodman David Malcom
Chief Medical Officer
|
- 5026
|
15.0016 USD |
|
3 months ago
Nov 06, 2024
|
Sell 383 K
USD
|
Rodman David Malcom
Chief Medical Officer
|
- 25482
|
15.0328 USD |
|
4 months ago
Oct 11, 2024
|
Sell 146 K
USD
|
Levy Adam Scott
CFO and Secretary
|
- 10757
|
13.5729 USD |
|
4 months ago
Oct 11, 2024
|
Sell 206 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 15271
|
13.518 USD |
|
7 months ago
Jul 24, 2024
|
Sell 7.18 M
USD
|
Slingsby Brian Taylor
director, 10 percent owner:
|
- 550000
|
13.05 USD |
|
7 months ago
Jul 16, 2024
|
Sell 7.88 K
USD
|
Rodman David Malcom
Chief Medical Officer
|
- 525
|
15.0011 USD |
|
7 months ago
Jul 11, 2024
|
Sell 141 K
USD
|
Levy Adam Scott
CFO and Secretary
|
- 10757
|
13.1444 USD |
|
7 months ago
Jul 11, 2024
|
Sell 210 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 15746
|
13.3415 USD |
|
8 months ago
Jun 17, 2024
|
Sell 218 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 17766
|
12.2544 USD |
|
8 months ago
Jun 18, 2024
|
Sell 199 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 16607
|
11.9873 USD |
|
8 months ago
Jun 20, 2024
|
Sell 175 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 14940
|
11.7294 USD |
|
8 months ago
Jun 12, 2024
|
Sell 212 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 16607
|
12.7665 USD |
|
8 months ago
Jun 13, 2024
|
Sell 509 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 39961
|
12.7381 USD |
|
8 months ago
Jun 14, 2024
|
Sell 203 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 16229
|
12.5185 USD |
|
8 months ago
Jun 11, 2024
|
Sell 1.25 M
USD
|
Levy Adam Scott
CFO and Secretary
|
- 96815
|
12.9393 USD |
|
9 months ago
May 09, 2024
|
Sell 1.5 K
USD
|
Rodman David Malcom
Chief Medical Officer
|
- 100
|
15 USD |
|
1 year ago
Feb 12, 2024
|
Bought
7.5 M USD
|
Samsara BioCapital GP, LLC
10 percent owner
|
+ 555555
|
13.5 USD |
|
1 year ago
Nov 22, 2023
|
Bought
25.4 K USD
|
Congleton Jon
Chief Executive Officer
|
+ 4250
|
5.9661 USD |
|
1 year ago
Sep 06, 2023
|
Bought
27.2 K USD
|
Congleton Jon
Chief Executive Officer
|
+ 2250
|
12.08 USD |
|
1 year ago
Aug 17, 2023
|
Bought
27.2 K USD
|
Congleton Jon
Chief Executive Officer
|
+ 2250
|
12.1 USD |
|
1 year ago
Aug 10, 2023
|
Sell 982 K
USD
|
Rodman David Malcom
Chief Medical Officer
|
- 74625
|
13.16 USD |
|
1 year ago
Aug 11, 2023
|
Sell 976 K
USD
|
Rodman David Malcom
Chief Medical Officer
|
- 76182
|
12.81 USD |
|
1 year ago
Aug 11, 2023
|
Bought
25.8 K USD
|
Congleton Jon
Chief Executive Officer
|
+ 2000
|
12.89 USD |
|
2 years ago
Feb 14, 2023
|
Bought
5 M USD
|
HBM Healthcare Investments (Cayman) Ltd.
10 percent owner
|
+ 312500
|
16 USD |
|
2 years ago
Feb 14, 2023
|
Bought
2.11 M USD
|
RA CAPITAL MANAGEMENT, L.P.
Director
|
+ 131600
|
16 USD |
|
2 years ago
Feb 14, 2023
|
Bought
17.9 M USD
|
RA CAPITAL MANAGEMENT, L.P.
Director
|
+ 1118400
|
16 USD |
7. News
Mineralys Therapeutics, Inc. (MLYS) Q4 2024 Earnings Call Transcript
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q4 2024 Results Conference Call February 12, 2025 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore ISI Rich Law - Goldman Sachs Annabel Samimy - Stifel Mohit Bansal - Wells Fargo Rami Khadkar - LifeSci Capital Matthew Caufield - H. C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the Mineralys Fourth Quarter and Full Year 2024 Earnings Conference Call.
seekingalpha.com
- 2 weeks ago
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
– Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 –
globenewswire.com
- 2 weeks ago
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025
RADNOR, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2024, before the financial markets open on Wednesday, February 12, 2025.
globenewswire.com
- 3 weeks ago
Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension
I believe Mineralys Therapeutics has a promising candidate with Lorundrostat for hypertension, CKD, and OSA. It should report more key pivotal clinical data this year. MLYS has several Phase 2 and 3 trials on Lorundrostat that could position it favorably for a potential FDA submission by late 2026 or sometime in 2027. According to the company's slides, Lorundrostat seems to have superior selectivity in some patients that reduces cortisol suppression and other side effects.
seekingalpha.com
- 1 month ago
Mineralys Therapeutics, Inc. (MLYS) Q3 2024 Earnings Call Transcript
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore Richard Law - Goldman Sachs Annabel Samimy - Stifel Rami Katkhuda - LifeSci Capital Matthew Caufield - H.C. Wainright Operator Greetings.
seekingalpha.com
- 3 months ago
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 – – Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.
globenewswire.com
- 3 months ago
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in fireside chats at three upcoming investor conferences.
globenewswire.com
- 3 months ago
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024
RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2024, after the financial markets close on Monday, November 11, 2024.
globenewswire.com
- 3 months ago
Mineralys Therapeutics Inc Is Being Investigated For Securities Law Violations And Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
- 4 months ago
The Schall Law Firm Encourages Investors To Join An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
- 4 months ago
Mineralys Therapeutics Inc Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
- 4 months ago
The Schall Law Firm Encourages Investors To Take Part In An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
- 4 months ago
8. Profile
Summary
Mineralys Therapeutics, Inc. MLYS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 455 M
Dividend Yield
0.00%
Description
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Contact
150 N. Radnor Chester Rd., Radnor, PA, 19087
https://mineralystx.com
IPO
Date
Feb. 10, 2023
Employees
51
Officers
Dr. Robert McKean Ph.D.
Senior Vice President of CMC
Mr. Adam Scott Levy
Chief Financial Officer & Secretary
Mr. Jeffrey N. Fellows
Senior Vice President of Regulatory Affairs
Dr. David M. Rodman M.D.
Chief Medical Officer
Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D.
Founder & Executive Director
Ms. Jessica Ibbitson
Senior Vice President of Clinical Operations
Ms. Cindy Berejikian
Executive Vice President of Operations
Ms. Sarah Foster
Vice President of Human Resources
Ms. Danielle Bradbury
Senior Vice President of Quality Assurance
Mr. Jon Congleton
Chief Executive Officer & Director